Virulence and arsenic resistance in Yersiniae

Neyt, Cécile; Iriarte, Maite; Thi, Vinh Ha; Cornelis, Guy R.

doi:10.1128/jb.179.3.612-619.1997

Cited by 119 publications

(115 citation statements)

References 61 publications

(46 reference statements)

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…In the presented strains it seems as if the region for the transposon extends beyond that described by Neyt, Iriarte, Thi and Cornelis (1997). Not only the Tn2502 region changes orientation in different plasmids, but also yscM2, yadA and yomA plus fragmented transposases surrounding yscM2.…”

Section: Btmentioning

confidence: 98%

“…Sequence similarity of the origin of replication in high-pathogenic pYVs to pYVs from low-pathogenic BTs is very low with 16% whereas protein identity is higher than 92% for the rest of the plasmid (Snellings, Popek and Lindler, 2001). Conversely, the origins of replication of both The arsenic resistance operon has been described as part of the transposon Tn2502 (Neyt, Iriarte, Thi and Cornelis, 1997 reported previously (Neyt, Iriarte, Thi and Cornelis, 1997). As the transposase is presumed to be non-functional in the described plasmid, it has been proposed that the acquisition event is ancient, and might be related to the worldwide spread of those biotypes where the arsenic resistance is thought to be of importance in environmental survival.…”

Section: Btmentioning

confidence: 99%

“…As pigs are thought to be one of the main reservoirs of Y. enterocolitica, their treatment with arsenic could have selected for plasmids carrying the operon (Neyt, Iriarte, Thi and Cornelis, 1997). Alternative arsenic resistance operons however are also found in BT 1B and BT 1A.…”

Section: Btmentioning

confidence: 99%

“…The chromosome or the plasmid can consequently carry arsenic resistance operons. pYV-independent arsenic resistance has been reported in the high-pathogenic BT 1B strain 8081 (Neyt, Iriarte, Thi and Cornelis, 1997), but nothing is known about functionality of arsenic resistance operons found in the nonpathogenic BT 1A.…”

Section: Btmentioning

confidence: 99%

“…The high-and non-pathogenic BTs on the other hand show the presence of operons for arsenic resistance on the chromosome, one of which is orthologous between the two BTs. In the last century and largely before World War II, arsenic has been used as a therapeutic agent in veterinary and human medicine, in particular in pigs (Neyt, Iriarte, Thi and Cornelis, 1997). This is specifically relevant as pigs are considered one of the main hosts outside the human and an important source of infections.…”

Section: The Virulence Plasmid Differs In High-and Low-pathogenic Btsmentioning

confidence: 99%

See 4 more Smart Citations

Evolutionary Dynamics of the Yersinia enterocolitica Complex

Reuter

Thomson

McNally

2012

Advances in Yersinia Research

View full text Add to dashboard Cite

Section: Btmentioning

confidence: 98%

Section: Btmentioning

confidence: 99%

Section: Btmentioning

confidence: 99%

Section: Btmentioning

confidence: 99%

Section: The Virulence Plasmid Differs In High-and Low-pathogenic Btsmentioning

confidence: 99%

See 3 more Smart Citations

Evolutionary Dynamics of the Yersinia enterocolitica Complex

Reuter

Thomson

McNally

2012

Advances in Yersinia Research

View full text Add to dashboard Cite

A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes

et al. 1999

View full text Add to dashboard Cite

The MAGE‐encoded antigens that are recognized by cytolytic T lymphocytes (CTL) are shared by many tumors and are strictly tumor specific. Clinical trials involving therapeutic vaccination of cancer patients with MAGE antigenic peptides or proteins are in progress. To increase the range of patients eligible for therapy with peptides, it is important to identify additional MAGE epitopes. We have used a method to identify CTL epitopes, which selects naturally processed peptides. CD8+ T cells, obtained from individuals without cancer, were stimulated with autologous dendritic cells infected with a recombinant adenovirus containing the MAGE‐A4 coding sequence. Responder cell microcultures that specifically lysed autologous EBV‐transformed B cells infected with vaccinia‐MAGE‐A4 were cloned using autologous stimulator cells infected with a Yersinia enterocolitica carrying the MAGE‐A4 sequence. An anti‐MAGE‐A4 CTL clone was obtained and the epitope was found to be decapeptide GVYDGREHTV (amino acids 230 – 239) presented by HLA‐A2 molecules. The CTL clone lysed HLA‐A2 tumor cells expressing MAGE‐A4. This is the first reported antigenic peptide encoded by MAGE‐A4. It may be valuable for cancer immunotherapy because MAGE‐A4 is expressed in 51 % of lung carcinomas and 63 % of esophageal carcinomas, whereas about 50 % of Caucasians and Asians express HLA‐A2.

show abstract